Drug maker Novo Nordisk is testing high doses of its type 2 diabetes drug Victoza as a possible treatment for obesity. However, analysts are questioning whether it will work well enough to be a commercial success. Victoza was initially marketed by Novo Nordisk using celebrity chef Paula Deen. The company quickly discontinued the contract with Deen after the Southern chef was heavily criticized for making racist remarks. The drug is in a class of medications known as glucagon-like peptide 1 dugs, or GLP-1. Other drugs in this group include Byetta, made by Bristol-Myers Squibb and AstraZeneca. GLP-1 drugs are in ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.